You are viewing the site in preview mode

Skip to main content

Advertisement

Table 2 Study population: patient characteristics

From: The impact of generic-only drug benefits on patients' use of inhaled corticosteroids in a Medicare population with asthma

  Total Unrestricted Coverage Restricted Coverage
Characteristic   Lower-cost ICS User in 2003 Higher-cost ICS User in 2003 Lower-cost ICS User in 2003 Higher-cost ICS User in 2003
No. subjects 1,802 293 175 847 487
Female* 67.7% 63.8% 65.7% 68.8% 68.8%
Age: 65–74 63.5% 60.4% 57.7% 62.6% 69.2%
   75–84 31.4% 33.8% 38.9% 31.6% 26.7%
   85+ 5.1% 5.8% 3.4% 5.8% 4.1%
Race/ethnicity*: White 68.1% 71.0% 70.3% 67.1% 67.4%
   Black 4.4% 7.2% 6.3% 2.8% 4.9%
   Hispanic 6.9% 3.1% 2.9% 8.5% 8.0%
   Asian 10.8% 10.6% 12.6% 10.5% 10.9%
   Other 3.2% 3.8% 3.4% 3.1% 3.1%
   Unknown 6.5% 4.4% 4.6% 8.0% 5.8%
Neighborhood SES*: Non-low 80.4% 84.0% 83.4% 78.3% 80.9%
   Low 17.7% 14.3% 14.9% 19.5% 17.7%
   Unknown 1.9% 1.7% 1.7% 2.2% 1.4%
Coronary Artery Disease 10.9% 11.3% 12.6% 10.6% 10.5%
Diabetes 15.5% 14.0% 15.4% 15.9% 15.6%
Heart Failure* 5.7% 8.2% 6.9% 5.4% 4.1%
Hypertension 55.9% 61.8% 55.4% 56.9% 50.7%
Exceeded $1,000 drug cap in 2003 -- -- -- 21.3% 44.2%
  Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD)
Comorbidity (DxCG) score* 0.94 (0.57) 1.00 (0.65) 1.02 (0.60) 0.94 (0.57) 0.89 (0.51)
  1. Notes: Lower-cost ICS Users in 2003 defined as patients with greater use of lower-cost than higher-cost ICS drugs in 2003. The 2003 diagnostic cost group (DxCG) score was calculated based on prior year diagnoses and procedures [DxCG Inc., Waltham, MA]. The range for the DxCG score was 0.24 to 5.48, median = 0.79.
  2. * p < .05 for difference between unrestricted and restricted coverage